A Phase 3 interventional study of Tofacitinib and Tofacitinib in Arthritis, Psoriatic, sponsored by Pfizer. Completed at 153 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-21.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing tofacitinib in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. tofacitinib · Arthritis, Psoriatic.
Among the 10 studies testing tofacitinib in Arthritis, Psoriatic, this one is the 2nd largest by enrollment, is one of 2 that started in 2014, is one of 7 in phase 3, and was the 4th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →2 of the 10 studies testing tofacitinib in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 686 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 237 across the 10 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 6 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
29 studies in Arthritis, Psoriatic by Pfizer: 1 open now, 1 under way, none of them phase 3. Of 28 finished, 22 (79%) have results posted.
Among the 29 studies in Arthritis, Psoriatic by Pfizer, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2014, is one of 6 in phase 3, and was the 18th registered.
Pfizer’s Arthritis, Psoriatic studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing tofacitinib in Arthritis, Psoriatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 29 in Arthritis, Psoriatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, long-term open-label extension study to evaluate the safety, tolerability and efficacy of tofacitinib in subjects with active PsA who have previously participated in randomized studies of tofacitinib for this indication.
This study will include a sub-study to evaluate the efficacy, safety and tolerability of tofacitinib 5 mg BID administered as monotherapy after methotrexate withdrawal compared to tofacitinib 5 mg BID continued in combination with methotrexate. The sub-study will be available to subjects who have completed at least 24 months of participation in the open-label extension study and meet eligibility criteria for the sub-study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sub-study Inclusion Criteria:
Sub-study Exclusion Criteria:
-Subjects who are receiving methotrexate by a route other than oral
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tofacitinib · Drug: Methotrexate · Drug: Placebo Methotrexate
Tofacitinib 5 mg tablet twice daily
Tofactinib 10 mg tablet twice daily
Methotrexate 7.5-20 mg weekly
Also known as: Sub-study
Placebo to match active methotrexate orally once a week
Also known as: Sub-study
Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 48 months that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious AEs.
Time frame: Date of first dose of study medication up to 48 months (36 months of main study and 12 months of sub-study)
Number of Adverse Events (AEs) by Severity
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified into 3 categories according to their severity as mild AEs (did not interfere with participant's usual function), moderate AEs (interfered to some extent with participant's usual function) and severe AEs (interfered significantly with participant's usual function).
Time frame: Date of first dose of study medication up to 48 months (36 months of main study and 12 months of sub-study)
Number of Participants With Abnormal Clinical Laboratory Values
Laboratory tests: hematology (Hb, hematocrit, RBC count, platelets, reticulocytes, WBC count, count and absolute lymphocytes,neutrophils, basophils, eosinophils, monocytes. Liver function (bilirubin \[total, direct, indirect\], AST, ALT, alkaline phosphatase, gamma-glutamyl transferase, albumin, total protein), renal function (blood urea nitrogen, creatinine), Lipids (cholesterol, HDL, LDL, triglyceride, apolipoprotein \[A-1, B\]), electrolytes (sodium, potassium, chloride, calcium, biocarbonate), chemistry (glucose, HbA1c, creatinine kinapse), urinalysis dipstick(urine pH, glucose, ketones, protein, blood, leukocyte, esterase), urinalysis microscopy (urine- RBC, WBC, bacteria, epithelial cells),C-reactive protein. Laboratory abnormality: determined by investigator per pre-defined criteria.
Time frame: Date of first dose of study medication up to 48 months (36 months of main study and 12 months of sub-study)
Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Values
Laboratory tests: hematology (Hb, hematocrit, RBC count, platelets, reticulocytes, WBC count, count and absolute lymphocytes, neutrophils, basophils, eosinophils, monocytes. Liver function (bilirubin\[total,direct,indirect\], AST, ALT, alkaline phosphatase, gamma-glutamyl transferase, albumin, total protein), renal function (blood urea nitrogen, creatinine), Lipids(cholesterol, HDL, LDL, triglyceride, apolipoprotein \[A-1, B\]), electrolytes (sodium, potassium, chloride, calcium, biocarbonate), chemistry (glucose, HbA1c, creatinine kinapse), urinalysis dipstick(urine-pH, glucose, ketones, protein, blood, leukocyte, esterase), urinalysis microscopy(urine- RBC, WBC, bacteria, epithelial cells),C-reactive protein. Clinically significant change: determined by investigator per pre-defined criteria.
Time frame: Date of first dose of study medication (Baseline) up to 48 months (36 months of main study and 12 months of sub-study)
Sub-study: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Month 6
HAQ-DI assessed the degree of difficulty a participant had experienced during the past week in 8 domains of daily living activities: dressing/grooming, arising, eating, walking, reach, grip, hygiene, and other activities. There were total of 2-3 items distributed in each of these 8 domains. Each item was scored for level of difficulty on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible HAQ-DI score ranged from 0 (least difficulty) to 3 (extreme difficulty), where higher score indicated more difficulty while performing daily living activities.
Time frame: Sub-study: Baseline (Day 1), Month 6
Sub-study: Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6
PASDAS was composite PsA disease activity score that included following components: Physician and patient global assessment of disease activity (assessed on a 0-100 VAS) in millimeter (mm), swollen (66 joints) and tender joint counts (68 joints), Leeds enthesitis index (enthesitis assessed at 6 sites; total score of 0-6), tender dactylitic digit score (scored on a scale of 0-3, where 0= no tenderness and 3= extreme tenderness), short form-36 questionnaire (SF-36) physical component summary (norm-based domain scores were used in analyses; with a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity) and C-reactive protein (CRP) in milligram per liter (mg/L). PASDAS was composite score and was a weighted index with score range of 0 to 10, where higher score indicated more severe disease.
Time frame: Sub-study: Baseline (Day 1), Month 6
Main Study: Percentage of Participants Achieving an American College of Rheumatology 20 Percent (%) (ACR20) Response
Participants with 20% improvement from baseline in tender and swollen joint counts and 20% improvement in at least 3 of the 5 measures: Patient's global assessment of arthritis (PtGA), Physician's global assessment of arthritis (PhyGA), participant's assessment of arthritis pain, HAQ-DI and C-reactive protein (CRP) in mg/L. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.
Time frame: Main Study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Main Study: Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response
Participants with 50% improvement from baseline in tender and swollen joint counts and 50% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, HAQ-DI and CRP in mg/L. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.
Time frame: Main Study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Main Study: Percentage of Participants Achieving an American College of Rheumatology 70% (ACR70) Response
Participants with 70% improvement from baseline in tender and swollen joint counts and 70% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, HAQ-DI and CRP in mg/L. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.
Time frame: Main Study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Main Study: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
HAQ-DI assessed the degree of difficulty a participant had experienced during the past week in 8 domains of daily living activities: dressing/grooming, arising, eating, walking, reach, grip, hygiene, and other activities. There were total of 2-3 items distributed in each of these 8 domains. Each item was scored for level of difficulty on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain score and divided by the number of domains answered. Total possible HAQ-DI score range 0 (least difficulty) and 3 (extreme difficulty), where higher score indicated more difficulty while performing daily living activities.
Time frame: Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Main Study: Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)
PsARC is comprised of 4 clinical improvement criteria: greater than or equal to (\>=) 20% improvement in PhyGA (VAS), \>=20% improvement in PtGA; and \>= 30% reduction in the number of tender joints; and \>=30% reduction in the number of swollen joints. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. To achieve a clinical response, the participant must improve in 2 of the 4 PsARC criteria, 1 of which has to be the number of tender or swollen joints and none of the 4 score could worsen.
Time frame: Main Study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Main Study: Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Score (For Participants With Baseline PGA-PsO Score Greater Than [>]0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
The PGA-PsO was a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0-4). Higher score indicated higher disease severity. Severity score for each erythema, induration and scaling were summed and averaged after which the total average was rounded to the nearest whole number score to determine a PGA-PsO score on a scale of 0 to 4 (0= clear, except for any residual discoloration, 1= almost clear, 2= mild, 3= moderate, 4= severe).
Time frame: Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Main Study: Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Score (For Participants With Baseline Body Surface Area [BSA]>=3% and Baseline PASI Score >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
PASI: combined assessment of lesion severity and body area affected into single score; range =0 (no disease) -72 (maximal disease). Higher score representing greater severity of psoriasis. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks). For each section % area of skin involved was estimated: 0 (0%) - 6 (90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1 =slight, 2 =moderate, 3 =marked, 4 =very marked. Final PASI =sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI75: at least a 75 % reduction in PASI relative to Baseline.
Time frame: Main study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Main Study: Percent Change From Baseline in PASI Composite Score (For Participants With Baseline BSA>=3% and Baseline PASI Score >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
PASI: combined assessment of lesion severity \& area affected into single score; range=0(no disease)-72(maximal disease). Higher score representing greater severity of psoriasis. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks). For each section % area of skin involved was estimated: 0(0%) - 6(90-100%) \& severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).
Time frame: Main study: Baseline, Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Main Study: Percent Change From Baseline in PASI Clinical Signs Component Score (For Participants With Baseline BSA>=3% and Baseline PASI Score >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
PASI: combined assessment of lesion severity \& area affected into single score; range=0(no disease)-72(maximal disease). Higher score representing greater severity of psoriasis. PASI is a composite scoring by investigator of degree of clinical sign components for erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks). For each section % area of skin involved was estimated: 0(0%) - 6(90-100%) and severity estimated by clinical signs components for erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).
Time frame: Main study: Baseline(Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Main Study: Change From Baseline in Dactylitis Severity Score (DSS) (For Participants With Baseline DSS Greater Than [>] 0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Dactylitis was characterized by swelling of the entire finger or toe. The DSS was a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis was scored on a scale of 0-3, where 0 =no tenderness and 3 =extreme tenderness in each digit of the hands and feet. The range of total dactylitis severity score for a participant was 0-60. Higher score indicated greater severity.
Time frame: Main study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Main Study: Change From Baseline in Leeds Enthesitis Index (LEI) (For Participants With Baseline LEI >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.
Time frame: Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Main Study: Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index (For Participants With Baseline SPARCC Enthesitis Index >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
The SPARCC enthesitis index identifies the presence or absence of tenderness at 16 enthesial sites, including (right and left): medial epicondyle humerus, lateral epicondyle humerus, supraspinatus insertion into greater tuberosity of humerus, greater trochanter, quadriceps insertion into superior border of patella, patellar ligament insertion into inferior pole of patella or tibial tubercle, Achilles tendon insertion into calcaneum and plantar fascia insertion into calcaneum. On examination, tenderness was recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicated a greater number of sites that are affected by enthesitis.
Time frame: Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Main Study: Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score (For Participants With Presence of Spondylitis at Screening and Baseline BASDAI Score >0 cm) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
BASDAI was a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0-10 cm (0= none and 10= very severe) participants answered 6 questions pertaining to 5 symptoms including fatigue, spinal pain, joint pain/swelling, areas of localized tenderness and morning stiffness. The final BASDAI score was an average of answers to 6 questions, with an overall possible score range of 0 to 10 centimeter (cm) with higher score represented more severe ankylosing spondylitis disease activity.
Time frame: Main study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Main Study: Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score (For Participants With Presence of Spondylitis at Screening and Baseline BASDAI Score >=4 cm) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
BASDAI was a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0-10 cm (0= none and 10= very severe) participants answered 6 questions pertaining to 5 symptoms including fatigue, spinal pain, joint pain/swelling, areas of localized tenderness and morning stiffness. The final BASDAI score was an average of answers to 6 questions, with an overall possible score range of 0 to 10 cm with higher score represented more severe ankylosing spondylitis disease activity.
Time frame: Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Component Summary Score at Months 1, 6, 12, 18, 24, 30 and 36
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 8 health domains were aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Norm-based domain scores, PCS and MCS scores were used in the analyses; each of which has a population mean of 50 with a standard deviation (SD) of 10 points, and ranges from minus infinity to plus infinity. A higher PCS score represented better physical health status.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Mental Component Summary Score at Months 1, 6, 12, 18, 24, 30, and 36
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher MCS score represents better mental health status.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Functioning Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
SF-36v2 was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 10 items of the physical functioning scale represented levels and kinds of limitations between extremes of physical activities, including lifting and carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence and extent of physical limitations using a 3-level response continuum. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher physical functioning domain score represented better physical functioning.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Role-Physical Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
SF-36v2 acute was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 4-item role-physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; \& d) accomplishing less. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-physical domain score represented better role-physical functioning.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Bodily Pain Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher bodily pain domain score represented less bodily pain.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) General Health Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The general health scale consisted of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher general health domain score represented better general health perceptions.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Vitality Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher vitality domain score represents better vitality.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Social Functioning Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 2-item social functioning scale assessed health-related effects on quantity and quality of social activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher social functioning domain score represented better social functioning.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2 ) Role-Emotional Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 3-item role-emotional scale assessed mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher role-emotional domain score represented better role-emotional functioning.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2 ) Mental Health Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher mental health domain score represented better mental health functioning.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Main Study: Change From Baseline in EuroQol- 5D Health Questionnaire 3-Level (EQ-5D-3L) Mobility Domain at Months 1, 6, 12, 18, 24, 30 and 36
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L mobility domain score were reported in this outcome measure.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30 and 36
Main Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Self-Care Domain at Months 1, 6, 12, 18, 24, 30 and 36
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L self-care domain score were reported in this measure.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Main Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Usual Activities Domain at Months 1, 6, 12, 18, 24, 30 and 36
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L usual activities domain score were reported in this measure.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Main Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Pain/Discomfort Domain at Months 1, 6, 12, 18, 24, 30 and 36
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L pain/discomfort domain score were reported in this measure.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Main Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Anxiety/Depression Domain at Months 1, 6, 12, 18, 24, 30 and 36
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L anxiety/depression domain score were reported in this outcome measure.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Main Study: Change From Baseline in EuroQol - Visual Analog Scale (EQ-VAS) Your Own Health State Today Domain at Months 1, 6, 12, 18, 24, 30 and 36
The EQ VAS recorded the participant's self-rated health on a vertical VAS as standard vertical 0 (worst imaginable health state) to 100 mm (best imaginable health state) (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state; higher score indicated a better health state.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Main Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score at Months 1, 6, 12, 18, 24, 30 and 36
FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52):calculated by summing 13 items,higher score indicated lower level of fatigue, better participant status. All responses were added with equal weight to get total score.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Main Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Experience Domain Score at Months 1, 6, 12, 18, 24, 30 and 36
FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Main Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Impact Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.
Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Sub-study: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Months 1, 3, 9 and 12
HAQ-DI assessed the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming, arising, eating, walking, reach, grip, hygiene, and other activities. There were total of 2-3 items distributed in each of these 8 domains. Each item was scored for level of difficulty on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain score and divided by the number of domains answered. Total possible HAQ-DI score range 0 (least difficulty) and 3 (extreme difficulty), where higher score indicated more difficulty while performing daily living activities.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 9 and 12
Sub-study: Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at Months 1, 3, 9 and 12
PASDAS was composite PsA disease activity score that included following components: Physician and patient global assessment of disease activity (assessed on a 0-100 VAS) in mm, swollen (66 joints) and tender joint counts (68 joints), Leeds enthesitis index (enthesitis assessed at 6 sites; total score of 0-6), tender dactylitic digit score (scored on a scale of 0-3, where 0= no tenderness and 3= extreme tenderness), SF-36 physical component summary (norm-based domain score were used in analyses; with a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity) and CRP in mg/L. PASDAS was composite score and was a weighted index with score range of 0 to 10, where higher score indicated more severe disease.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 9 and 12
Sub-study: Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC) at Months 1, 3, 6, 9 and 12
PsARC was comprised of 4 clinical improvement criteria: \>=20% improvement in PhyGA (VAS), \>=20% improvement in PtGA; and \>= 30% reduction in the number of tender joints; and \>=30% reduction in the number of swollen joints. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. To achieve a clinical response, the participant must improve in 2 of the 4 PsARC criteria, 1 of which has to be the number of tender or swollen joints and none of the 4 score could worsen.
Time frame: Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Score (For Participants With Baseline PGA-PsO Score >0 ) at Months 1, 3, 6, 9 and 12
The PGA-PsO is a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0-4). Higher score indicated higher disease severity. Severity score for each erythema, induration and scaling were summed and averaged after which the total average was rounded to the nearest whole number score to determine a PGA-PsO score on a scale of 0 to 4 (0= clear, except for any residual discoloration, 1= almost clear, 2= mild, 3= moderate, 4= severe).
Time frame: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Percent Change From Baseline in Body Surface Area (BSA) (For Participants With BSA >0%) Psoriasis at Months 1, 3, 6, 9 and 12
Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage (Head and neck = 10 handprints \[1 handprint =10%\], upper extremities = 20 handprints \[1 handprint =5%\], Trunk (including axillae and groin) = 30 handprints \[1 handprint =3.33%\], lower extremities (including buttocks) = 40 handprints \[1 handprint =2.5%\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in Dactylitis Severity Score (DSS) (For Participants With Baseline DSS >0) at Months 1, 3, 6, 9 and 12
Dactylitis was characterized by swelling of the entire finger or toe. The DSS was a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis was scored on a scale of 0-3, where 0 =no tenderness and 3 =extreme tenderness in each digit of the hands and feet. The range of total dactylitis score for a participant was 0-60. Higher score indicated greater degree of tenderness.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Percentage of Participants With Absence of Dactylitis (For Participants With Baseline DSS >0) at Months 1, 3, 6, 9 and 12
Dactylitis was characterized by swelling of the entire finger or toe. The DSS was a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis was scored on a scale of 0-3, where 0 =no tenderness and 3 =extreme tenderness in each digit of the hands and feet. The range of total dactylitis score for a participant was 0-60. Higher score indicated greater degree of tenderness.
Time frame: Sub-study: Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in Leeds Enthesitis Index (LEI) (For Participants With Baseline LEI >0) at Months 1, 3, 6, 9 and 12
Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and Achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Leeds Enthesitis Index (LEI) (For Participants With Baseline LEI =0) at Months 1, 3, 6, 9 and 12
Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and Achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.
Time frame: Sub-study: Months 1, 3, 6, 9 and 12
Sub-study: Percentage of Participants With Absence of Enthesitis Assessed Using Leeds Enthesitis Index (LEI) (For Participants With Baseline LEI >0) at Months 1, 3, 6, 9 and 12
Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.
Time frame: Sub-study: Months 1, 3, 6, 9 and 12
Sub-study: Percentage of Participants With Minimal Disease Activity (MDA) at Months 1, 3, 6, 9 and 12
A psoriatic arthritis participant was considered with minimal disease activity if participant had \>= 5 of 7 criteria: 1) tender/painful joint count less than or equals to (\<=) 1; (2) swollen joint count \<=1; (3) BSA \<=3%; (4) Patient Assessment of Arthritis Pain (VAS) \<=15 mm; (5) PtGA (VAS) \<=20 mm; (6) HAQ-DI score \<=0.5; (7) tender entheseal points (using LEI) \<=1.
Time frame: Sub-study: Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in Tender/Painful Joint Count at Months 1, 3, 6, 9 and 12
68 joints were assessed to determine joints that are considered tender or painful. Response to pressure/motion on each joint was assessed using the following scale: Present/Absent/Not Done/Done/Not Applicable (to be used for artificial or missing joints). The 68 joints assessed were: 1) Upper Body: temporomandibular, sternoclavicular, acromioclavicular. 2) Upper Extremity: shoulder, elbow, wrist (includes radiocarpal, carpal and carpometacarpal considered as one unit), metacarpophalangeals (MCP I, II, III, IV, V), thumb interphalangeal (IP), proximal interphalangeals (PIP II, III, IV, V), distal interphalangeals (DIP II, III, IV, V). 3) Lower Extremity: hip, knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), metatarsophalangeals (MTP I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in Swollen Joint Count at Months 1, 3, 6, 9 and 12
Joints were assessed for swelling using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). Sixty-six (66) joints were assessed for swelling. The 66 joints assessed were: 1) Upper Body: temporomandibular, sternoclavicular, acromioclavicular. 2) Upper Extremity: shoulder, elbow, wrist (includes radiocarpal, carpal and carpometacarpal considered as one unit), metacarpophalangeals (MCP I, II, III, IV, V), thumb interphalangeal (IP), proximal interphalangeals (PIP II, III, IV, V), distal interphalangeals (DIP II, III, IV, V). 3) Lower Extremity: knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), metatarsophalangeals (MTP I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in Physician's Global Assessment of Arthritis (PhyGA) at Months 1, 3, 6, 9 and 12
The investigator or qualified assessor assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and independent of the PtGA and Patient Assessment of Arthritis Pain. The investigator's response was recorded using a 100 mm VAS where 0 =PSA not active at all and 100 =PSA extremely active. Higher score indicated more PSA.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in Patient's Global Assessment of Arthritis (PtGA) at Months 1, 3, 6, 9 and 12
Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participant's response were recorded using a 0 - 100 mm VAS where 0 =not affected at all and 100 =extremely affected. Higher score indicated worse condition due to PSA.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in Patient's Assessment of Arthritis Pain at Months 1, 3, 6, 9 and 12
Participants assessed the severity of their arthritis pain using a 100 mm VAS by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain. Higher score indicated more severe pain.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in C-Reactive Protein (CRP) at Months 1, 3, 6, 9 and 12
The test for CRP was a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Component Summary Score at Months 1, 3, 6, 9 and 12
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a standard deviation (SD) of 10 points, and ranges from minus infinity to plus infinity. A higher PCS score represents better physical health status.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Mental Component Summary Score at Months 1, 3, 6, 9 and 12
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher MCS score represents better mental health status.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Functioning Domain Score at Months 1, 3, 6, 9 and 12
SF-36v2 was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 10 items of the physical functioning scale represented levels and kinds of limitations between extremes of physical activities, including lifting \& carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence \& extent of physical limitations using a 3-level response continuum. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher physical functioning domain score represented better physical functioning.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Role Physical Domain Score at Months 1, 3, 6, 9 and 12
SF-36v2 acute was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 4-item role-physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; \& d) accomplishing less. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-physical domain score represented better role-physical functioning.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Bodily Pain Domain Score at Months 1, 3, 6, 9 and 12
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher bodily pain domain score represented less bodily pain.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) General Health Domain Score at Months 1, 3, 6, 9 and 12
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The general health scale consisted of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher general health domain score represented better general health perceptions.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Vitality Domain Score at Months 1, 3, 6, 9 and 12
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher vitality domain score represented better vitality.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Social Functioning Domain Score at Months 1, 3, 6, 9 and 12
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 2-item social functioning scale assessed health-related effects on quantity and quality of social activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher social functioning domain score represented better social functioning.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Role Emotional Domain Score at Months 1, 3, 6, 9 and 12
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 3-item role-emotional scale assessed mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher role-emotional domain score represented better role-emotional functioning.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Mental Health Domain Score at Months 1, 3, 6, 9 and 12
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher mental health domain score represented better mental health functioning.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score at Months 1, 3, 6, 9 and 12
FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52):calculated by summing 13 items,higher score indicated lower level of fatigue, better participant status. All responses were added with equal weight to get total score.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Experience Domain Score at Months 1, 3, 6, 9 and 12
FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Impact Domain Score at Months 1, 3, 6, 9 and 12
FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Mobility Domain at Months 1, 3, 6, 9 and 12
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L mobility domain score were reported in this measure.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Self-Care Domain at Months 1, 3, 6, 9 and 12
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L self-care domain score were reported in this measure.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Usual Activities Domain at Months 1, 3, 6, 9 and 12
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L usual activities domain score were reported in this measure.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Pain/Discomfort Domain
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L pain/discomfort domain score were reported in this measure.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Anxiety/Depression Domain at Months 1, 3, 6, 9 and 12
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L anxiety/depression domain score were reported in this measure.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Sub Study: Change From Baseline in EuroQol - Visual Analog Scale (EQ-VAS) Your Own Health State Today Domain at Months 1, 3, 6, 9 and 12
The EQ VAS recorded the participant's self-rated health on a vertical VAS as standard verticle 0 (worst imaginable health state) to 100 mm (best imaginable health state) (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state; higher score indicated a better health state.
Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Eligible participants (who had previously participated in randomized psoriatic arthritis \[PsA\] clinical studies with tofacitinib) from qualifying studies A3921091 (NCT01877668) and A3921125 (NCT01882439) were enrolled into this current study A3921092 (NCT01976364).
| Milestone | Tofacitinib | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|---|
| Started | 686 | 0 | 0 |
| Completed | 465 | 0 | 0 |
| Not completed | 221 | 0 | 0 |
| Withdrew: Adverse event | 63 | 0 | 0 |
| Withdrew: Withdrawn due to pregnancy | 5 | 0 | 0 |
| Withdrew: Other | 13 | 0 | 0 |
| Withdrew: No longer met eligibility criteria | 2 | 0 | 0 |
| Withdrew: Medication error | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 10 | 0 | 0 |
| Withdrew: Lack of efficacy | 40 | 0 | 0 |
| Withdrew: Protocol violation | 13 | 0 | 0 |
| Withdrew: Withdrawal by subject | 69 | 0 | 0 |
| Withdrew: Death | 5 | 0 | 0 |
| Milestone | Tofacitinib | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|---|
| Started | 0 | 89 | 90 |
| Completed | 0 | 83 | 85 |
| Not completed | 0 | 6 | 5 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 4 | 3 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 48 months that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious AEs.
| percentage of participants | All Participants |
|---|---|
| AEs | 83.7 |
| SAEs | 16.8 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified into 3 categories according to their severity as mild AEs (did not interfere with participant's usual function), moderate AEs (interfered to some extent with participant's usual function) and severe AEs (interfered significantly with participant's usual function).
| adverse events | All Participants |
|---|---|
| Number of adverse events: Mild | 1632 |
| Number of adverse events: Moderate | 1045 |
| Number of adverse events: Severe | 136 |
Laboratory tests: hematology (Hb, hematocrit, RBC count, platelets, reticulocytes, WBC count, count and absolute lymphocytes,neutrophils, basophils, eosinophils, monocytes. Liver function (bilirubin \[total, direct, indirect\], AST, ALT, alkaline phosphatase, gamma-glutamyl transferase, albumin, total protein), renal function (blood urea nitrogen, creatinine), Lipids (cholesterol, HDL, LDL, triglyceride, apolipoprotein \[A-1, B\]), electrolytes (sodium, potassium, chloride, calcium, biocarbonate), chemistry (glucose, HbA1c, creatinine kinapse), urinalysis dipstick(urine pH, glucose, ketones, protein, blood, leukocyte, esterase), urinalysis microscopy (urine- RBC, WBC, bacteria, epithelial cells),C-reactive protein. Laboratory abnormality: determined by investigator per pre-defined criteria.
| Participants | All Participants |
|---|---|
| Number of Participants With Abnormal Clinical Laboratory Values | 646 |
Laboratory tests: hematology (Hb, hematocrit, RBC count, platelets, reticulocytes, WBC count, count and absolute lymphocytes, neutrophils, basophils, eosinophils, monocytes. Liver function (bilirubin\[total,direct,indirect\], AST, ALT, alkaline phosphatase, gamma-glutamyl transferase, albumin, total protein), renal function (blood urea nitrogen, creatinine), Lipids(cholesterol, HDL, LDL, triglyceride, apolipoprotein \[A-1, B\]), electrolytes (sodium, potassium, chloride, calcium, biocarbonate), chemistry (glucose, HbA1c, creatinine kinapse), urinalysis dipstick(urine-pH, glucose, ketones, protein, blood, leukocyte, esterase), urinalysis microscopy(urine- RBC, WBC, bacteria, epithelial cells),C-reactive protein. Clinically significant change: determined by investigator per pre-defined criteria.
| Participants | All Participants |
|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Values | 9 |
HAQ-DI assessed the degree of difficulty a participant had experienced during the past week in 8 domains of daily living activities: dressing/grooming, arising, eating, walking, reach, grip, hygiene, and other activities. There were total of 2-3 items distributed in each of these 8 domains. Each item was scored for level of difficulty on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible HAQ-DI score ranged from 0 (least difficulty) to 3 (extreme difficulty), where higher score indicated more difficulty while performing daily living activities.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Sub-study: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Month 6 | 0.0174 ± 0.02775 | 0.0428 ± 0.02714 |
PASDAS was composite PsA disease activity score that included following components: Physician and patient global assessment of disease activity (assessed on a 0-100 VAS) in millimeter (mm), swollen (66 joints) and tender joint counts (68 joints), Leeds enthesitis index (enthesitis assessed at 6 sites; total score of 0-6), tender dactylitic digit score (scored on a scale of 0-3, where 0= no tenderness and 3= extreme tenderness), short form-36 questionnaire (SF-36) physical component summary (norm-based domain scores were used in analyses; with a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity) and C-reactive protein (CRP) in milligram per liter (mg/L). PASDAS was composite score and was a weighted index with score range of 0 to 10, where higher score indicated more severe disease.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Sub-study: Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6 | 0.138 ± 0.0805 | 0.229 ± 0.0786 |
Participants with 20% improvement from baseline in tender and swollen joint counts and 20% improvement in at least 3 of the 5 measures: Patient's global assessment of arthritis (PtGA), Physician's global assessment of arthritis (PhyGA), participant's assessment of arthritis pain, HAQ-DI and C-reactive protein (CRP) in mg/L. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.
| percentage of participants | Tofacitinib |
|---|---|
| Month 1 | 66.12 (62.55 to 69.70) |
| Month 3 | 68.79 (65.25 to 72.32) |
| Month 6 | 70.66 (67.12 to 74.21) |
| Month 9 | 71.48 (67.87 to 75.08) |
| Month 12 | 74.18 (70.62 to 77.74) |
| Month 15 | 78.04 (74.58 to 81.50) |
| Month 18 | 77.65 (74.13 to 81.18) |
| Month 21 | 77.00 (73.40 to 80.59) |
| Month 24 | 76.13 (72.43 to 79.82) |
| Month 27 | 78.18 (74.54 to 81.82) |
| Month 30 | 80.79 (77.27 to 84.32) |
| Month 33 | 77.88 (74.05 to 81.70) |
| Month 36 | 77.02 (72.81 to 81.24) |
Participants with 50% improvement from baseline in tender and swollen joint counts and 50% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, HAQ-DI and CRP in mg/L. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.
| percentage of participants | Tofacitinib |
|---|---|
| Month 1 | 45.70 (41.94 to 49.46) |
| Month 3 | 43.27 (39.49 to 47.04) |
| Month 6 | 47.08 (43.19 to 50.97) |
| Month 9 | 50.41 (46.43 to 54.40) |
| Month 12 | 50.26 (46.19 to 54.32) |
| Month 15 | 55.42 (51.28 to 59.55) |
| Month 18 | 55.10 (50.90 to 59.30) |
| Month 21 | 55.41 (51.16 to 59.65) |
| Month 24 | 57.34 (53.05 to 61.63) |
| Month 27 | 56.05 (51.68 to 60.42) |
| Month 30 | 60.46 (56.08 to 64.84) |
| Month 33 | 57.96 (53.41 to 62.52) |
| Month 36 | 58.85 (53.93 to 63.78) |
Participants with 70% improvement from baseline in tender and swollen joint counts and 70% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, HAQ-DI and CRP in mg/L. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.
| percentage of participants | Tofacitinib |
|---|---|
| Month 1 | 24.85 (21.59 to 28.11) |
| Month 3 | 26.13 (22.79 to 29.48) |
| Month 6 | 30.50 (26.92 to 34.08) |
| Month 9 | 30.81 (27.13 to 34.48) |
| Month 12 | 32.13 (28.34 to 35.92) |
| Month 15 | 33.87 (29.94 to 37.81) |
| Month 18 | 36.25 (32.18 to 40.31) |
| Month 21 | 34.35 (30.29 to 38.40) |
| Month 24 | 35.94 (31.78 to 40.09) |
| Month 27 | 38.10 (33.83 to 42.38) |
| Month 30 | 41.60 (37.17 to 46.02) |
| Month 33 | 38.19 (33.72 to 42.66) |
| Month 36 | 37.76 (32.91 to 42.61) |
HAQ-DI assessed the degree of difficulty a participant had experienced during the past week in 8 domains of daily living activities: dressing/grooming, arising, eating, walking, reach, grip, hygiene, and other activities. There were total of 2-3 items distributed in each of these 8 domains. Each item was scored for level of difficulty on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain score and divided by the number of domains answered. Total possible HAQ-DI score range 0 (least difficulty) and 3 (extreme difficulty), where higher score indicated more difficulty while performing daily living activities.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | -0.4373 ± 0.55677 |
| Change at Month 3 | -0.4559 ± 0.55104 |
| Change at Month 6 | -0.4755 ± 0.57468 |
| Change at Month 9 | -0.4841 ± 0.58294 |
| Change at Month 12 | -0.4782 ± 0.60163 |
| Change at Month 15 | -0.5108 ± 0.58277 |
| Change at Month 18 | -0.5116 ± 0.59401 |
| Change at Month 21 | -0.5211 ± 0.59568 |
| Change at Month 24 | -0.5068 ± 0.62016 |
| Change at Month 27 | -0.5219 ± 0.60833 |
| Change at Month 30 | -0.5356 ± 0.61316 |
| Change at Month 33 | -0.5276 ± 0.63803 |
| Change at Month 36 | -0.5476 ± 0.65226 |
PsARC is comprised of 4 clinical improvement criteria: greater than or equal to (\>=) 20% improvement in PhyGA (VAS), \>=20% improvement in PtGA; and \>= 30% reduction in the number of tender joints; and \>=30% reduction in the number of swollen joints. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. To achieve a clinical response, the participant must improve in 2 of the 4 PsARC criteria, 1 of which has to be the number of tender or swollen joints and none of the 4 score could worsen.
| percentage of participants | Tofacitinib |
|---|---|
| Month 1 | 68.46 (64.94 to 71.98) |
| Month 3 | 69.56 (66.04 to 73.08) |
| Month 6 | 73.14 (69.69 to 76.60) |
| Month 9 | 74.46 (70.97 to 77.95) |
| Month 12 | 76.08 (72.60 to 79.56) |
| Month 15 | 79.52 (76.14 to 82.91) |
| Month 18 | 80.15 (76.77 to 83.53) |
| Month 21 | 79.50 (76.04 to 82.96) |
| Month 24 | 77.51 (73.88 to 81.15) |
| Month 27 | 80.16 (76.65 to 83.68) |
| Month 30 | 82.11 (78.66 to 85.55) |
| Month 33 | 80.85 (77.21 to 84.49) |
| Month 36 | 77.17 (72.95 to 81.38) |
The PGA-PsO was a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0-4). Higher score indicated higher disease severity. Severity score for each erythema, induration and scaling were summed and averaged after which the total average was rounded to the nearest whole number score to determine a PGA-PsO score on a scale of 0 to 4 (0= clear, except for any residual discoloration, 1= almost clear, 2= mild, 3= moderate, 4= severe).
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | -1.1 ± 1.04 |
| Change at Month 3 | -1.1 ± 1.04 |
| Change at Month 6 | -1.2 ± 1.03 |
| Change at Month 9 | -1.2 ± 1.06 |
| Change at Month 12 | -1.1 ± 1.06 |
| Change at Month 15 | -1.2 ± 1.07 |
| Change at Month 18 | -1.2 ± 1.05 |
| Change at Month 21 | -1.2 ± 1.06 |
| Change at Month 24 | -1.3 ± 1.02 |
| Change at Month 27 | -1.3 ± 1.02 |
| Change at Month 30 | -1.3 ± 1.05 |
| Change at Month 33 | -1.3 ± 1.02 |
| Change at Month 36 | -1.2 ± 1.02 |
PASI: combined assessment of lesion severity and body area affected into single score; range =0 (no disease) -72 (maximal disease). Higher score representing greater severity of psoriasis. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks). For each section % area of skin involved was estimated: 0 (0%) - 6 (90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1 =slight, 2 =moderate, 3 =marked, 4 =very marked. Final PASI =sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI75: at least a 75 % reduction in PASI relative to Baseline.
| percentage of participants | Tofacitinib |
|---|---|
| Month 1 | 55.05 (50.53 to 59.58) |
| Month 3 | 57.96 (53.41 to 62.52) |
| Month 6 | 60.74 (56.14 to 65.34) |
| Month 9 | 61.07 (56.36 to 65.78) |
| Month 12 | 63.16 (58.42 to 67.89) |
| Month 15 | 65.71 (60.95 to 70.47) |
| Month 18 | 65.22 (60.35 to 70.08) |
| Month 21 | 69.72 (64.98 to 74.47) |
| Month 24 | 71.47 (66.72 to 76.22) |
| Month 27 | 70.85 (66.04 to 75.66) |
| Month 30 | 68.58 (63.58 to 73.58) |
| Month 33 | 70.10 (65.01 to 75.18) |
| Month 36 | 68.08 (62.41 to 73.74) |
PASI: combined assessment of lesion severity \& area affected into single score; range=0(no disease)-72(maximal disease). Higher score representing greater severity of psoriasis. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks). For each section % area of skin involved was estimated: 0(0%) - 6(90-100%) \& severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).
| percent change | Tofacitinib |
|---|---|
| At Month 1 | -64.09 ± 57.473 |
| At Month 3 | -66.98 ± 43.647 |
| At Month 6 | -68.58 ± 44.568 |
| At Month 9 | -70.42 ± 40.617 |
| At Month 12 | -71.58 ± 42.515 |
| At Month 15 | -73.13 ± 43.653 |
| At Month 18 | -73.51 ± 40.527 |
| At Month 21 | -75.15 ± 44.182 |
| At Month 24 | -78.36 ± 34.808 |
| At Month 27 | -78.37 ± 34.405 |
| At Month 30 | -78.28 ± 30.270 |
| At Month 33 | -77.47 ± 43.952 |
| At Month 36 | -76.85 ± 31.973 |
PASI: combined assessment of lesion severity \& area affected into single score; range=0(no disease)-72(maximal disease). Higher score representing greater severity of psoriasis. PASI is a composite scoring by investigator of degree of clinical sign components for erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks). For each section % area of skin involved was estimated: 0(0%) - 6(90-100%) and severity estimated by clinical signs components for erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).
| percent change | Tofacitinib |
|---|---|
| Induration: At Month 1 | -62.60 ± 62.288 |
| Induration: At Month 3 | -66.92 ± 46.898 |
| Induration: At Month 6 | -68.63 ± 46.644 |
| Induration: At Month 9 | -70.33 ± 41.960 |
| Induration: At Month 12 | -70.81 ± 48.439 |
| Induration: At Month 15 | -72.49 ± 48.644 |
| Induration: At Month 18 | -73.16 ± 40.801 |
| Induration: At Month 21 | -74.34 ± 47.617 |
| Induration: At Month 24 | -78.45 ± 36.534 |
| Induration: At Month 27 | -77.85 ± 34.297 |
| Induration: At Month 30 | -78.55 ± 31.187 |
| Induration: At Month 33 | -77.09 ± 42.305 |
| Induration: At Month 36 | -76.11 ± 35.000 |
| Erythema: At Month 1 | -63.60 ± 67.818 |
| Erythema: At Month 3 | -66.69 ± 43.013 |
| Erythema: At Month 6 | -67.17 ± 46.756 |
| Erythema: At Month 9 | -69.75 ± 42.882 |
| Erythema: At Month 12 | -70.45 ± 46.575 |
| Erythema: At Month 15 | -71.55 ± 50.406 |
| Erythema: At Month 18 | -73.12 ± 45.194 |
| Erythema: At Month 21 | -75.06 ± 45.993 |
| Erythema: At Month 24 | -77.40 ± 38.093 |
| Erythema: At Month 27 | -77.83 ± 33.877 |
| Erythema: At Month 30 | -77.04 ± 33.478 |
| Erythema: At Month 33 | -75.17 ± 53.782 |
| Erythema: At Month 36 | -75.72 ± 34.823 |
| Scaling: At Month 1 | -64.26 ± 55.848 |
| Scaling: At Month 3 | -66.15 ± 52.568 |
| Scaling: At Month 6 | -68.66 ± 49.145 |
| Scaling: At Month 9 | -69.09 ± 48.506 |
| Scaling: At Month 12 | -72.48 ± 45.755 |
| Scaling: At Month 15 | -73.83 ± 42.528 |
| Scaling: At Month 18 | -74.62 ± 39.708 |
| Scaling: At Month 21 | -75.11 ± 44.570 |
| Scaling: At Month 24 | -77.86 ± 38.041 |
| Scaling: At Month 27 | -79.34 ± 31.825 |
| Scaling: At Month 30 | -77.23 ± 37.819 |
| Scaling: At Month 33 | -77.94 ± 41.688 |
| Scaling: At Month 36 | -78.10 ± 30.391 |
Dactylitis was characterized by swelling of the entire finger or toe. The DSS was a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis was scored on a scale of 0-3, where 0 =no tenderness and 3 =extreme tenderness in each digit of the hands and feet. The range of total dactylitis severity score for a participant was 0-60. Higher score indicated greater severity.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | -6.7 ± 7.65 |
| Change at Month 3 | -6.8 ± 7.71 |
| Change at Month 6 | -7.2 ± 7.89 |
| Change at Month 9 | -7.4 ± 7.29 |
| Change at Month 12 | -7.6 ± 7.70 |
| Change at Month 15 | -7.7 ± 7.44 |
| Change at Month 18 | -7.7 ± 7.50 |
| Change at Month 21 | -7.8 ± 7.89 |
| Change at Month 24 | -7.9 ± 7.76 |
| Change at Month 27 | -8.1 ± 7.59 |
| Change at Month 30 | -8.0 ± 7.65 |
| Change at Month 33 | -8.1 ± 7.75 |
| Change at Month 36 | -7.7 ± 7.88 |
Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | -1.5 ± 1.88 |
| Change at Month 3 | -1.6 ± 1.79 |
| Change at Month 6 | -1.7 ± 1.78 |
| Change at Month 9 | -1.8 ± 1.80 |
| Change at Month 12 | -1.7 ± 1.82 |
| Change at Month 15 | -2.0 ± 1.76 |
| Change at Month 18 | -1.9 ± 1.79 |
| Change at Month 21 | -1.9 ± 1.81 |
| Change at Month 24 | -2.0 ± 1.72 |
| Change at Month 27 | -2.0 ± 1.73 |
| Change at Month 30 | -2.0 ± 1.76 |
| Change at Month 33 | -2.0 ± 1.75 |
| Change at Month 36 | -2.1 ± 1.76 |
The SPARCC enthesitis index identifies the presence or absence of tenderness at 16 enthesial sites, including (right and left): medial epicondyle humerus, lateral epicondyle humerus, supraspinatus insertion into greater tuberosity of humerus, greater trochanter, quadriceps insertion into superior border of patella, patellar ligament insertion into inferior pole of patella or tibial tubercle, Achilles tendon insertion into calcaneum and plantar fascia insertion into calcaneum. On examination, tenderness was recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicated a greater number of sites that are affected by enthesitis.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | -2.8 ± 3.60 |
| Change at Month 3 | -3.0 ± 3.61 |
| Change at Month 6 | -3.2 ± 3.72 |
| Change at Month 9 | -3.4 ± 3.69 |
| Change at Month 12 | -3.5 ± 3.46 |
| Change at Month 15 | -3.7 ± 3.55 |
| Change at Month 18 | -3.5 ± 3.45 |
| Change at Month 21 | -3.6 ± 3.60 |
| Change at Month 24 | -3.7 ± 3.62 |
| Change at Month 27 | -3.7 ± 3.56 |
| Change at Month 30 | -3.8 ± 3.49 |
| Change at Month 33 | -3.9 ± 3.39 |
| Change at Month 36 | -3.9 ± 3.69 |
BASDAI was a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0-10 cm (0= none and 10= very severe) participants answered 6 questions pertaining to 5 symptoms including fatigue, spinal pain, joint pain/swelling, areas of localized tenderness and morning stiffness. The final BASDAI score was an average of answers to 6 questions, with an overall possible score range of 0 to 10 centimeter (cm) with higher score represented more severe ankylosing spondylitis disease activity.
| centimeter | Tofacitinib |
|---|---|
| Change at Month 1 | -2.26 ± 2.367 |
| Change at Month 3 | -2.10 ± 2.278 |
| Change at Month 6 | -2.40 ± 2.371 |
| Change at Month 9 | -2.35 ± 2.254 |
| Change at Month 12 | -2.41 ± 2.371 |
| Change at Month 15 | -2.35 ± 2.547 |
| Change at Month 18 | -2.41 ± 2.640 |
| Change at Month 21 | -2.28 ± 2.582 |
| Change at Month 24 | -2.47 ± 2.640 |
| Change at Month 27 | -2.65 ± 2.658 |
| Change at Month 30 | -2.95 ± 2.672 |
| Change at Month 33 | -2.85 ± 2.671 |
| Change at Month 36 | -2.88 ± 2.521 |
BASDAI was a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0-10 cm (0= none and 10= very severe) participants answered 6 questions pertaining to 5 symptoms including fatigue, spinal pain, joint pain/swelling, areas of localized tenderness and morning stiffness. The final BASDAI score was an average of answers to 6 questions, with an overall possible score range of 0 to 10 cm with higher score represented more severe ankylosing spondylitis disease activity.
| centimeter | Tofacitinib |
|---|---|
| Change at Month 1 | -2.59 ± 2.324 |
| Change at Month 3 | -2.41 ± 2.227 |
| Change at Month 6 | -2.74 ± 2.350 |
| Change at Month 9 | -2.63 ± 2.175 |
| Change at Month 12 | -2.65 ± 2.364 |
| Change at Month 15 | -2.65 ± 2.487 |
| Change at Month 18 | -2.65 ± 2.652 |
| Change at Month 21 | -2.47 ± 2.602 |
| Change at Month 24 | -2.72 ± 2.616 |
| Change at Month 27 | -2.90 ± 2.640 |
| Change at Month 30 | -3.27 ± 2.596 |
| Change at Month 33 | -3.17 ± 2.589 |
| Change at Month 36 | -3.08 ± 2.459 |
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 8 health domains were aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Norm-based domain scores, PCS and MCS scores were used in the analyses; each of which has a population mean of 50 with a standard deviation (SD) of 10 points, and ranges from minus infinity to plus infinity. A higher PCS score represented better physical health status.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | 6.44 ± 8.285 |
| Change at Month 6 | 6.71 ± 8.496 |
| Change at Month 12 | 7.23 ± 8.257 |
| Change at Month 18 | 7.44 ± 8.729 |
| Change at Month 24 | 7.79 ± 9.055 |
| Change at Month 30 | 8.06 ± 8.899 |
| Change at Month 36 | 7.77 ± 9.074 |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher MCS score represents better mental health status.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | 4.72 ± 10.480 |
| Change at Month 6 | 4.98 ± 11.052 |
| Change at Month 12 | 5.25 ± 11.072 |
| Change at Month 18 | 5.53 ± 11.055 |
| Change at Month 24 | 5.79 ± 11.122 |
| Change at Month 30 | 5.82 ± 11.726 |
| Change at Month 36 | 6.18 ± 11.284 |
SF-36v2 was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 10 items of the physical functioning scale represented levels and kinds of limitations between extremes of physical activities, including lifting and carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence and extent of physical limitations using a 3-level response continuum. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher physical functioning domain score represented better physical functioning.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | 6.06 ± 9.425 |
| Change at Month 6 | 6.44 ± 9.834 |
| Change at Month 12 | 7.00 ± 9.472 |
| Change at Month 18 | 7.31 ± 9.891 |
| Change at Month 24 | 7.69 ± 10.280 |
| Change at Month 30 | 7.96 ± 10.146 |
| Change at Month 36 | 7.80 ± 10.703 |
SF-36v2 acute was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 4-item role-physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; \& d) accomplishing less. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-physical domain score represented better role-physical functioning.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | 6.19 ± 9.545 |
| Change at Month 6 | 6.56 ± 9.650 |
| Change at Month 12 | 6.61 ± 9.293 |
| Change at Month 18 | 7.07 ± 10.050 |
| Change at Month 24 | 7.46 ± 10.094 |
| Change at Month 30 | 7.64 ± 10.041 |
| Change at Month 36 | 7.40 ± 9.996 |
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher bodily pain domain score represented less bodily pain.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | 8.36 ± 9.797 |
| Change at Month 6 | 8.52 ± 10.033 |
| Change at Month 12 | 9.29 ± 9.777 |
| Change at Month 18 | 9.70 ± 10.271 |
| Change at Month 24 | 9.95 ± 10.980 |
| Change at Month 30 | 10.21 ± 10.645 |
| Change at Month 36 | 10.45 ± 10.627 |
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The general health scale consisted of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher general health domain score represented better general health perceptions.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | 3.89 ± 8.033 |
| Change at Month 6 | 4.09 ± 8.640 |
| Change at Month 12 | 4.68 ± 8.652 |
| Change at Month 18 | 4.76 ± 8.386 |
| Change at Month 24 | 4.89 ± 8.608 |
| Change at Month 30 | 4.81 ± 8.590 |
| Change at Month 36 | 4.36 ± 8.847 |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher vitality domain score represents better vitality.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | 5.92 ± 10.160 |
| Change at Month 6 | 6.03 ± 10.546 |
| Change at Month 12 | 6.72 ± 10.367 |
| Change at Month 18 | 6.67 ± 10.147 |
| Change at Month 24 | 7.10 ± 10.828 |
| Change at Month 30 | 7.62 ± 10.808 |
| Change at Month 36 | 7.65 ± 10.403 |
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 2-item social functioning scale assessed health-related effects on quantity and quality of social activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher social functioning domain score represented better social functioning.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | 6.08 ± 11.028 |
| Change at Month 6 | 6.51 ± 10.923 |
| Change at Month 12 | 7.16 ± 10.932 |
| Change at Month 18 | 6.76 ± 11.272 |
| Change at Month 24 | 7.28 ± 11.487 |
| Change at Month 30 | 7.64 ± 11.597 |
| Change at Month 36 | 7.83 ± 11.977 |
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 3-item role-emotional scale assessed mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher role-emotional domain score represented better role-emotional functioning.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | 5.40 ± 11.962 |
| Change at Month 6 | 5.39 ± 12.445 |
| Change at Month 12 | 5.73 ± 12.235 |
| Change at Month 18 | 6.71 ± 12.647 |
| Change at Month 24 | 6.82 ± 12.154 |
| Change at Month 30 | 6.54 ± 12.843 |
| Change at Month 36 | 6.95 ± 12.859 |
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher mental health domain score represented better mental health functioning.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | 4.85 ± 10.306 |
| Change at Month 6 | 5.39 ± 10.893 |
| Change at Month 12 | 5.56 ± 10.781 |
| Change at Month 18 | 5.82 ± 10.730 |
| Change at Month 24 | 6.09 ± 11.247 |
| Change at Month 30 | 6.18 ± 11.278 |
| Change at Month 36 | 6.37 ± 11.199 |
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L mobility domain score were reported in this outcome measure.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | -0.24 ± 0.529 |
| Change at Month 6 | -0.30 ± 0.540 |
| Change at Month 12 | -0.28 ± 0.511 |
| Change at Month 18 | -0.30 ± 0.538 |
| Change at Month 24 | -0.31 ± 0.545 |
| Change at Month 30 | -0.30 ± 0.526 |
| Change at Month 36 | -0.32 ± 0.555 |
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L self-care domain score were reported in this measure.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | -0.19 ± 0.547 |
| Change at Month 6 | -0.20 ± 0.530 |
| Change at Month 12 | -0.19 ± 0.532 |
| Change at Month 18 | -0.21 ± 0.522 |
| Change at Month 24 | -0.21 ± 0.534 |
| Change at Month 30 | -0.23 ± 0.533 |
| Change at Month 36 | -0.24 ± 0.589 |
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L usual activities domain score were reported in this measure.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | -0.27 ± 0.588 |
| Change at Month 6 | -0.30 ± 0.539 |
| Change at Month 12 | -0.33 ± 0.547 |
| Change at Month 18 | -0.32 ± 0.579 |
| Change at Month 24 | -0.36 ± 0.547 |
| Change at Month 30 | -0.34 ± 0.571 |
| Change at Month 36 | -0.35 ± 0.594 |
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L pain/discomfort domain score were reported in this measure.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | -0.31 ± 0.557 |
| Change at Month 6 | -0.32 ± 0.570 |
| Change at Month 12 | -0.36 ± 0.568 |
| Change at Month 18 | -0.40 ± 0.584 |
| Change at Month 24 | -0.41 ± 0.602 |
| Change at Month 30 | -0.41 ± 0.601 |
| Change at Month 36 | -0.40 ± 0.613 |
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L anxiety/depression domain score were reported in this outcome measure.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | -0.23 ± 0.600 |
| Change at Month 6 | -0.26 ± 0.623 |
| Change at Month 12 | -0.25 ± 0.594 |
| Change at Month 18 | -0.26 ± 0.604 |
| Change at Month 24 | -0.29 ± 0.605 |
| Change at Month 30 | -0.31 ± 0.608 |
| Change at Month 36 | -0.29 ± 0.651 |
The EQ VAS recorded the participant's self-rated health on a vertical VAS as standard vertical 0 (worst imaginable health state) to 100 mm (best imaginable health state) (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state; higher score indicated a better health state.
| millimeter | Tofacitinib |
|---|---|
| Change at Month 1 | 14.12 ± 24.928 |
| Change at Month 6 | 15.71 ± 25.871 |
| Change at Month 12 | 16.00 ± 24.896 |
| Change at Month 18 | 16.68 ± 24.746 |
| Change at Month 24 | 17.43 ± 25.226 |
| Change at Month 30 | 17.87 ± 25.363 |
| Change at Month 36 | 18.07 ± 25.185 |
FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52):calculated by summing 13 items,higher score indicated lower level of fatigue, better participant status. All responses were added with equal weight to get total score.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | 7.0 ± 9.78 |
| Change at Month 6 | 7.7 ± 10.13 |
| Change at Month 12 | 7.8 ± 9.70 |
| Change at Month 18 | 8.1 ± 10.06 |
| Change at Month 24 | 8.3 ± 10.61 |
| Change at Month 30 | 8.7 ± 10.93 |
| Change at Month 36 | 9.1 ± 11.05 |
FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | 3.1 ± 4.47 |
| Change at Month 6 | 3.4 ± 4.61 |
| Change at Month 12 | 3.5 ± 4.48 |
| Change at Month 18 | 3.6 ± 4.63 |
| Change at Month 24 | 3.7 ± 4.93 |
| Change at Month 30 | 3.9 ± 5.02 |
| Change at Month 36 | 4.0 ± 4.90 |
FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.
| units on a scale | Tofacitinib |
|---|---|
| Change at Month 1 | 3.9 ± 5.98 |
| Change at Month 6 | 4.2 ± 6.19 |
| Change at Month 12 | 4.4 ± 5.88 |
| Change at Month 18 | 4.5 ± 6.05 |
| Change at Month 24 | 4.6 ± 6.34 |
| Change at Month 30 | 4.8 ± 6.46 |
| Change at Month 36 | 5.0 ± 6.77 |
HAQ-DI assessed the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming, arising, eating, walking, reach, grip, hygiene, and other activities. There were total of 2-3 items distributed in each of these 8 domains. Each item was scored for level of difficulty on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain score and divided by the number of domains answered. Total possible HAQ-DI score range 0 (least difficulty) and 3 (extreme difficulty), where higher score indicated more difficulty while performing daily living activities.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -0.0164 ± 0.02438 | 0.0322 ± 0.02411 |
| Change at Month 3 | 0.0057 ± 0.02512 | 0.0381 ± 0.02474 |
| Change at Month 9 | 0.0720 ± 0.03195 | 0.0663 ± 0.03125 |
| Change at Month 12 | 0.0467 ± 0.02998 | 0.0563 ± 0.02941 |
PASDAS was composite PsA disease activity score that included following components: Physician and patient global assessment of disease activity (assessed on a 0-100 VAS) in mm, swollen (66 joints) and tender joint counts (68 joints), Leeds enthesitis index (enthesitis assessed at 6 sites; total score of 0-6), tender dactylitic digit score (scored on a scale of 0-3, where 0= no tenderness and 3= extreme tenderness), SF-36 physical component summary (norm-based domain score were used in analyses; with a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity) and CRP in mg/L. PASDAS was composite score and was a weighted index with score range of 0 to 10, where higher score indicated more severe disease.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | 0.000 ± 0.0701 | 0.032 ± 0.0696 |
| Change at Month 3 | 0.188 ± 0.0869 | 0.165 ± 0.0868 |
| Change at Month 9 | 0.158 ± 0.0934 | 0.371 ± 0.0912 |
| Change at Month 12 | 0.194 ± 0.0898 | 0.133 ± 0.0882 |
PsARC was comprised of 4 clinical improvement criteria: \>=20% improvement in PhyGA (VAS), \>=20% improvement in PtGA; and \>= 30% reduction in the number of tender joints; and \>=30% reduction in the number of swollen joints. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. To achieve a clinical response, the participant must improve in 2 of the 4 PsARC criteria, 1 of which has to be the number of tender or swollen joints and none of the 4 score could worsen.
| percentage of participants | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Month 1 | 12.36 | 12.22 |
| Month 3 | 11.24 | 6.67 |
| Month 6 | 12.36 | 6.67 |
| Month 9 | 12.36 | 10.00 |
| Month 12 | 13.48 | 3.33 |
The PGA-PsO is a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0-4). Higher score indicated higher disease severity. Severity score for each erythema, induration and scaling were summed and averaged after which the total average was rounded to the nearest whole number score to determine a PGA-PsO score on a scale of 0 to 4 (0= clear, except for any residual discoloration, 1= almost clear, 2= mild, 3= moderate, 4= severe).
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -0.1 ± 0.10 | 0.2 ± 0.11 |
| Change at Month 3 | -0.1 ± 0.12 | 0.1 ± 0.14 |
| Change at Month 6 | -0.1 ± 0.11 | 0.2 ± 0.12 |
| Change at Month 9 | -0.3 ± 0.13 | 0.2 ± 0.13 |
| Change at Month 12 | 0.0 ± 0.15 | 0.3 ± 0.15 |
Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage (Head and neck = 10 handprints \[1 handprint =10%\], upper extremities = 20 handprints \[1 handprint =5%\], Trunk (including axillae and groin) = 30 handprints \[1 handprint =3.33%\], lower extremities (including buttocks) = 40 handprints \[1 handprint =2.5%\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.
| percent change | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| At Month 1 | 28.47 ± 13.497 | 9.04 ± 13.972 |
| At Month 3 | 43.58 ± 18.679 | 13.47 ± 19.348 |
| At Month 6 | 41.51 ± 20.745 | 17.19 ± 21.157 |
| At Month 9 | 35.36 ± 17.309 | 23.72 ± 17.691 |
| At Month 12 | 34.74 ± 19.909 | 41.75 ± 20.333 |
Dactylitis was characterized by swelling of the entire finger or toe. The DSS was a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis was scored on a scale of 0-3, where 0 =no tenderness and 3 =extreme tenderness in each digit of the hands and feet. The range of total dactylitis score for a participant was 0-60. Higher score indicated greater degree of tenderness.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -0.4 ± 0.79 | 0.0 ± NA |
| Change at Month 3 | -0.3 ± 0.52 | -1.0 ± NA |
| Change at Month 6 | -0.3 ± 0.52 | -1.0 ± NA |
| Change at Month 9 | -0.3 ± 0.52 | -1.0 ± NA |
| Change at Month 12 | -0.3 ± 0.52 | -1.0 ± NA |
Dactylitis was characterized by swelling of the entire finger or toe. The DSS was a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis was scored on a scale of 0-3, where 0 =no tenderness and 3 =extreme tenderness in each digit of the hands and feet. The range of total dactylitis score for a participant was 0-60. Higher score indicated greater degree of tenderness.
| percentage of participants | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Month 1 | 14.29 | 0.0 |
| Month 3 | 14.29 | 0.0 |
| Month 6 | 14.29 | 0.0 |
| Month 9 | 14.29 | 0.0 |
| Month 12 | 14.29 | 0.0 |
Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and Achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -0.2 ± 0.25 | -0.4 ± 0.24 |
| Change at Month 3 | -0.3 ± 0.23 | -0.5 ± 0.23 |
| Change at Month 6 | -0.5 ± 0.29 | -0.7 ± 0.28 |
| Change at Month 9 | -0.3 ± 0.29 | 0.0 ± 0.28 |
| Change at Month 12 | -0.5 ± 0.28 | -0.3 ± 0.27 |
Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and Achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Month 1 | 0.2 ± 0.64 | 0.1 ± 0.58 |
| Month 3 | 0.2 ± 0.56 | 0.0 ± 0.24 |
| Month 6 | 0.2 ± 0.76 | 0.2 ± 0.82 |
| Month 9 | 0.1 ± 0.24 | 0.1 ± 0.46 |
| Month 12 | 0.2 ± 0.67 | 0.1 ± 0.49 |
Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.
| percentage of participants | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Month 1 | 13.33 | 25.00 |
| Month 3 | 13.33 | 43.75 |
| Month 6 | 26.67 | 56.25 |
| Month 9 | 13.33 | 37.50 |
| Month 12 | 26.67 | 43.75 |
A psoriatic arthritis participant was considered with minimal disease activity if participant had \>= 5 of 7 criteria: 1) tender/painful joint count less than or equals to (\<=) 1; (2) swollen joint count \<=1; (3) BSA \<=3%; (4) Patient Assessment of Arthritis Pain (VAS) \<=15 mm; (5) PtGA (VAS) \<=20 mm; (6) HAQ-DI score \<=0.5; (7) tender entheseal points (using LEI) \<=1.
| percentage of participants | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Month 1 | 50.56 | 55.56 |
| Month 3 | 50.56 | 54.44 |
| Month 6 | 46.07 | 48.89 |
| Month 9 | 42.70 | 46.67 |
| Month 12 | 41.57 | 44.44 |
68 joints were assessed to determine joints that are considered tender or painful. Response to pressure/motion on each joint was assessed using the following scale: Present/Absent/Not Done/Done/Not Applicable (to be used for artificial or missing joints). The 68 joints assessed were: 1) Upper Body: temporomandibular, sternoclavicular, acromioclavicular. 2) Upper Extremity: shoulder, elbow, wrist (includes radiocarpal, carpal and carpometacarpal considered as one unit), metacarpophalangeals (MCP I, II, III, IV, V), thumb interphalangeal (IP), proximal interphalangeals (PIP II, III, IV, V), distal interphalangeals (DIP II, III, IV, V). 3) Lower Extremity: hip, knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), metatarsophalangeals (MTP I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).
| tender/painful joints | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | 0.7 ± 0.37 | 0.3 ± 0.37 |
| Change at Month 3 | 1.3 ± 0.44 | 0.9 ± 0.44 |
| Change at Month 6 | 0.5 ± 0.37 | 0.5 ± 0.37 |
| Change at Month 9 | 0.4 ± 0.33 | 0.4 ± 0.32 |
| Change at Month 12 | 0.3 ± 0.32 | 0.5 ± 0.32 |
Joints were assessed for swelling using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). Sixty-six (66) joints were assessed for swelling. The 66 joints assessed were: 1) Upper Body: temporomandibular, sternoclavicular, acromioclavicular. 2) Upper Extremity: shoulder, elbow, wrist (includes radiocarpal, carpal and carpometacarpal considered as one unit), metacarpophalangeals (MCP I, II, III, IV, V), thumb interphalangeal (IP), proximal interphalangeals (PIP II, III, IV, V), distal interphalangeals (DIP II, III, IV, V). 3) Lower Extremity: knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), metatarsophalangeals (MTP I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).
| swollen joints | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -0.1 ± 0.14 | 0.0 ± 0.14 |
| Change at Month 3 | 0.3 ± 0.21 | 0.3 ± 0.21 |
| Change at Month 6 | 0.1 ± 0.16 | 0.1 ± 0.15 |
| Change at Month 9 | 0.0 ± 0.17 | 0.2 ± 0.17 |
| Change at Month 12 | 0.1 ± 0.14 | 0.0 ± 0.14 |
The investigator or qualified assessor assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and independent of the PtGA and Patient Assessment of Arthritis Pain. The investigator's response was recorded using a 100 mm VAS where 0 =PSA not active at all and 100 =PSA extremely active. Higher score indicated more PSA.
| millimeter | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -0.42 ± 0.992 | -0.17 ± 0.981 |
| Change at Month 3 | 1.98 ± 1.225 | 2.76 ± 1.216 |
| Change at Month 6 | 1.18 ± 0.983 | 1.65 ± 0.966 |
| Change at Month 9 | 1.18 ± 1.316 | 3.35 ± 1.287 |
| Change at Month 12 | 0.86 ± 1.127 | 0.75 ± 1.111 |
Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participant's response were recorded using a 0 - 100 mm VAS where 0 =not affected at all and 100 =extremely affected. Higher score indicated worse condition due to PSA.
| millimeter | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | 1.35 ± 1.277 | -0.68 ± 1.264 |
| Change at Month 3 | 2.11 ± 1.537 | 1.68 ± 1.516 |
| Change at Month 6 | 3.17 ± 1.725 | 4.45 ± 1.690 |
| Change at Month 9 | 2.63 ± 1.691 | 3.27 ± 1.655 |
| Change at Month 12 | 2.77 ± 1.629 | 2.65 ± 1.602 |
Participants assessed the severity of their arthritis pain using a 100 mm VAS by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain. Higher score indicated more severe pain.
| millimeter | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -0.05 ± 1.383 | -1.16 ± 1.370 |
| Change at Month 3 | 1.59 ± 1.394 | 0.36 ± 1.380 |
| Change at Month 6 | 3.12 ± 1.709 | 4.07 ± 1.674 |
| Change at Month 9 | 2.44 ± 1.780 | 4.45 ± 1.741 |
| Change at Month 12 | 2.69 ± 1.692 | 3.35 ± 1.664 |
The test for CRP was a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay.
| mg/L | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -0.1171 ± 0.71654 | -0.2706 ± 0.70892 |
| Change at Month 3 | -0.3625 ± 0.48088 | -0.9285 ± 0.47675 |
| Change at Month 6 | 0.5354 ± 0.79954 | -0.2637 ± 0.78002 |
| Change at Month 9 | -0.3217 ± 0.59271 | -0.2591 ± 0.57983 |
| Change at Month 12 | -0.1005 ± 0.78650 | 0.2667 ± 0.77230 |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a standard deviation (SD) of 10 points, and ranges from minus infinity to plus infinity. A higher PCS score represents better physical health status.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -0.55 ± 0.424 | -0.22 ± 0.419 |
| Change at Month 3 | -0.90 ± 0.492 | -0.57 ± 0.487 |
| Change at Month 6 | -0.65 ± 0.480 | -1.42 ± 0.466 |
| Change at Month 9 | -1.09 ± 0.607 | -1.85 ± 0.593 |
| Change at Month 12 | -1.52 ± 0.533 | -1.00 ± 0.523 |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher MCS score represents better mental health status.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | 0.35 ± 0.630 | -0.11 ± 0.622 |
| Change at Month 3 | 0.09 ± 0.642 | -0.77 ± 0.634 |
| Change at Month 6 | -0.23 ± 0.733 | -0.89 ± 0.713 |
| Change at Month 9 | -0.71 ± 0.749 | 0.06 ± 0.731 |
| Change at Month 12 | -0.38 ± 0.694 | -0.47 ± 0.681 |
SF-36v2 was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 10 items of the physical functioning scale represented levels and kinds of limitations between extremes of physical activities, including lifting \& carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence \& extent of physical limitations using a 3-level response continuum. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher physical functioning domain score represented better physical functioning.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -0.37 ± 0.472 | -0.15 ± 0.467 |
| Change at Month 3 | -0.50 ± 0.562 | -0.33 ± 0.556 |
| Change at Month 6 | -0.27 ± 0.586 | -0.80 ± 0.571 |
| Change at Month 9 | -1.43 ± 0.657 | -1.11 ± 0.643 |
| Change at Month 12 | -1.01 ± 0.676 | -1.02 ± 0.664 |
SF-36v2 acute was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 4-item role-physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; \& d) accomplishing less. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-physical domain score represented better role-physical functioning.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -0.27 ± 0.561 | 0.22 ± 0.555 |
| Change at Month 3 | -1.04 ± 0.626 | 0.21 ± 0.619 |
| Change at Month 6 | -1.57 ± 0.585 | -0.87 ± 0.569 |
| Change at Month 9 | -0.64 ± 0.638 | -0.44 ± 0.624 |
| Change at Month 12 | -1.85 ± 0.646 | -0.12 ± 0.635 |
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher bodily pain domain score represented less bodily pain.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -0.77 ± 0.617 | -0.06 ± 0.609 |
| Change at Month 3 | -1.59 ± 0.661 | -1.24 ± 0.652 |
| Change at Month 6 | -0.61 ± 0.686 | -2.42 ± 0.669 |
| Change at Month 9 | -1.29 ± 0.808 | -3.05 ± 0.790 |
| Change at Month 12 | -1.69 ± 0.719 | -1.99 ± 0.706 |
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The general health scale consisted of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher general health domain score represented better general health perceptions.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | 0.20 ± 0.492 | -0.48 ± 0.487 |
| Change at Month 3 | 0.34 ± 0.516 | -0.79 ± 0.511 |
| Change at Month 6 | 0.24 ± 0.493 | -0.57 ± 0.481 |
| Change at Month 9 | -0.48 ± 0.562 | -0.46 ± 0.551 |
| Change at Month 12 | -0.32 ± 0.539 | -0.29 ± 0.530 |
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher vitality domain score represented better vitality.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -0.04 ± 0.614 | -0.39 ± 0.607 |
| Change at Month 3 | -0.26 ± 0.593 | -1.12 ± 0.586 |
| Change at Month 6 | 0.01 ± 0.705 | -1.70 ± 0.687 |
| Change at Month 9 | -0.80 ± 0.645 | -1.27 ± 0.632 |
| Change at Month 12 | -1.04 ± 0.640 | -0.09 ± 0.629 |
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 2-item social functioning scale assessed health-related effects on quantity and quality of social activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher social functioning domain score represented better social functioning.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -0.99 ± 0.734 | -0.22 ± 0.726 |
| Change at Month 3 | -0.80 ± 0.750 | -1.18 ± 0.740 |
| Change at Month 6 | -1.16 ± 0.776 | -1.74 ± 0.757 |
| Change at Month 9 | -1.50 ± 0.753 | -1.22 ± 0.737 |
| Change at Month 12 | -1.81 ± 0.758 | -1.28 ± 0.746 |
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 3-item role-emotional scale assessed mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher role-emotional domain score represented better role-emotional functioning.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | 1.14 ± 0.716 | -0.53 ± 0.707 |
| Change at Month 3 | 0.24 ± 0.807 | -0.38 ± 0.797 |
| Change at Month 6 | -0.72 ± 0.788 | -0.82 ± 0.769 |
| Change at Month 9 | -0.78 ± 0.803 | -0.06 ± 0.782 |
| Change at Month 12 | -0.33 ± 0.835 | -1.11 ± 0.820 |
The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher mental health domain score represented better mental health functioning.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -0.30 ± 0.676 | 0.63 ± 0.669 |
| Change at Month 3 | -0.42 ± 0.661 | -0.31 ± 0.653 |
| Change at Month 6 | -0.01 ± 0.780 | -0.26 ± 0.762 |
| Change at Month 9 | -0.72 ± 0.724 | 0.35 ± 0.710 |
| Change at Month 12 | -0.37 ± 0.723 | 0.01 ± 0.711 |
FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52):calculated by summing 13 items,higher score indicated lower level of fatigue, better participant status. All responses were added with equal weight to get total score.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -1.9 ± 0.61 | -1.1 ± 0.61 |
| Change at Month 3 | -1.8 ± 0.59 | -1.3 ± 0.58 |
| Change at Month 6 | -1.3 ± 0.61 | -2.0 ± 0.60 |
| Change at Month 9 | -2.1 ± 0.65 | -1.0 ± 0.64 |
| Change at Month 12 | -1.4 ± 0.66 | -0.7 ± 0.64 |
FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -0.9 ± 0.29 | -0.5 ± 0.29 |
| Change at Month 3 | -0.8 ± 0.31 | -0.9 ± 0.30 |
| Change at Month 6 | -0.5 ± 0.29 | -1.3 ± 0.28 |
| Change at Month 9 | -0.7 ± 0.31 | -0.8 ± 0.30 |
| Change at Month 12 | -0.5 ± 0.31 | -0.5 ± 0.31 |
FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | -1.1 ± 0.39 | -0.6 ± 0.39 |
| Change at Month 3 | -1.1 ± 0.35 | -0.4 ± 0.35 |
| Change at Month 6 | -0.8 ± 0.41 | -0.7 ± 0.40 |
| Change at Month 9 | -1.4 ± 0.42 | -0.2 ± 0.41 |
| Change at Month 12 | -0.9 ± 0.40 | -0.1 ± 0.40 |
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L mobility domain score were reported in this measure.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | 0.0 ± 0.04 | 0.0 ± 0.04 |
| Change at Month 3 | 0.0 ± 0.04 | 0.0 ± 0.04 |
| Change at Month 6 | 0.0 ± 0.04 | 0.1 ± 0.04 |
| Change at Month 9 | 0.0 ± 0.04 | 0.1 ± 0.04 |
| Change at Month 12 | 0.0 ± 0.04 | 0.1 ± 0.04 |
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L self-care domain score were reported in this measure.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | 0.0 ± 0.03 | 0.0 ± 0.03 |
| Change at Month 3 | 0.0 ± 0.03 | 0.0 ± 0.03 |
| Change at Month 6 | 0.0 ± 0.04 | 0.0 ± 0.03 |
| Change at Month 9 | 0.0 ± 0.04 | 0.0 ± 0.04 |
| Change at Month 12 | 0.0 ± 0.04 | 0.1 ± 0.04 |
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L usual activities domain score were reported in this measure.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | 0.0 ± 0.04 | 0.0 ± 0.04 |
| Change at Month 3 | 0.0 ± 0.04 | 0.0 ± 0.04 |
| Change at Month 6 | 0.0 ± 0.04 | 0.1 ± 0.04 |
| Change at Month 9 | 0.1 ± 0.04 | 0.1 ± 0.04 |
| Change at Month 12 | 0.0 ± 0.04 | 0.0 ± 0.04 |
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L pain/discomfort domain score were reported in this measure.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | 0.1 ± 0.04 | 0.0 ± 0.04 |
| Change at Month 3 | 0.1 ± 0.04 | 0.1 ± 0.04 |
| Change at Month 6 | 0.1 ± 0.04 | 0.1 ± 0.04 |
| Change at Month 9 | 0.1 ± 0.05 | 0.1 ± 0.05 |
| Change at Month 12 | 0.1 ± 0.05 | 0.2 ± 0.05 |
EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L anxiety/depression domain score were reported in this measure.
| units on a scale | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | 0.1 ± 0.04 | 0.0 ± 0.04 |
| Change at Month 3 | 0.0 ± 0.05 | 0.0 ± 0.04 |
| Change at Month 6 | 0.1 ± 0.05 | 0.0 ± 0.05 |
| Change at Month 9 | 0.1 ± 0.05 | 0.0 ± 0.05 |
| Change at Month 12 | 0.1 ± 0.05 | 0.0 ± 0.05 |
The EQ VAS recorded the participant's self-rated health on a vertical VAS as standard verticle 0 (worst imaginable health state) to 100 mm (best imaginable health state) (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state; higher score indicated a better health state.
| millimeter | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|
| Change at Month 1 | 2.0 ± 1.19 | -0.9 ± 1.16 |
| Change at Month 3 | 0.5 ± 1.54 | -1.1 ± 1.52 |
| Change at Month 6 | 4.4 ± 1.41 | -1.9 ± 1.38 |
| Change at Month 9 | 2.5 ± 1.59 | -0.4 ± 1.56 |
| Change at Month 12 | 3.0 ± 1.82 | -1.9 ± 1.78 |
Collected over Baseline (Day 1) up to last dose of main study (maximum up to 36 months) if not enrolled into sub-study or from baseline up to last dose of sub-study (maximum up to 48 months) if enrolled into sub-study. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Tofacitinib | 6/686 (0.9%) | 115/686 (16.8%) | 457/686 (66.6%) |
| Tofacitinib 5 mg BID + Methotrexate (MTX) | 0/89 (0%) | 3/89 (3.4%) | 25/89 (28.1%) |
| Tofacitinib 5 mg BID + Placebo | 0/90 (0%) | 4/90 (4.4%) | 24/90 (26.7%) |
| Event | All Tofacitinib | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|---|
| HaematemesisGastrointestinal disorders | 1/686 | 1/89 | 0/90 |
| MelaenaGastrointestinal disorders | 1/686 | 1/89 | 0/90 |
| AppendicitisInfections and infestations | 1/686 | 1/89 | 0/90 |
| Pneumonia herpes viralInfections and infestations | 1/686 | 1/89 | 0/90 |
| Psoriatic arthropathyMusculoskeletal and connective tissue disorders | 1/686 | 0/89 | 1/90 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/686 | 0/89 | 1/90 |
| ParaesthesiaNervous system disorders | 1/686 | 0/89 | 1/90 |
| Forearm fractureInjury, poisoning and procedural complications | 1/686 | 0/89 | 1/90 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 7/686 | 0/89 | 0/90 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 4/686 | 0/89 | 0/90 |
| Event | All Tofacitinib | Tofacitinib 5 mg BID + Methotrexate (MTX) | Tofacitinib 5 mg BID + Placebo |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 124/686 | 6/89 | 4/90 |
| NasopharyngitisInfections and infestations | 104/686 | 1/89 | 3/90 |
| BronchitisInfections and infestations | 67/686 | 2/89 | 3/90 |
| Urinary tract infectionInfections and infestations | 66/686 | 3/89 | 4/90 |
| HypertensionVascular disorders | 50/686 | 2/89 | 2/90 |
| Psoriatic arthropathyMusculoskeletal and connective tissue disorders | 44/686 | 3/89 | 0/90 |
| PharyngitisInfections and infestations | 38/686 | 3/89 | 3/90 |
| Blood creatine phosphokinase increasedInvestigations | 36/686 | 0/89 | 0/90 |
| Alanine aminotransferase increasedInvestigations | 34/686 | 0/89 | 0/90 |
| SinusitisInfections and infestations | 33/686 | 0/89 | 0/90 |
Safety analysis set (SAS) included all participants enrolled in this study who were part of a prior qualifying study, and who received at least one dose of open-label study medication in A3921092. Full analysis set (FAS) and the SAS were same in this study.
| Age, Continuous(years) | Tofacitinib: All Participants |
|---|---|
| Mean | 48.8 ± 11.8 |
| Sex: Female, Male(Participants) | Tofacitinib: All Participants |
|---|---|
| Female | 370 |
| Male | 316 |
| Race (NIH/OMB)(Participants) | Tofacitinib: All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 21 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 646 |
| More than one race | 17 |
| Unknown or Not Reported | 0 |
Showing the first 100 of 153 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Feb 2014 to primary completion in May 2019, 63 months.
Results were first posted in May 2020, 1 year after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 63 months is above that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib